Development of a combination therapy is showing significant promise in type 1 diabetes when caught in the early stages. What are some immuno-therapies currently being evaluated for treating type 1 diabetes? Join host Dr. Steven Edelman and his guest, director of the Center for Type 1 Diabetes Research at the La Jolla Institute for Allergy and Immunology, Dr. Matthias von Herrath, as they discuss histopathology, antigen-specific therapy, anti-CD3d antibodies and more.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
The Potential of Immunotherapy in Type 1 Diabetes
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Recommended
Details
Presenters
Comments
Recommended
Overview
Development of a combination therapy is showing significant promise in type 1 diabetes when caught in the early stages. What are some immuno-therapies currently being evaluated for treating type 1 diabetes? Join host Dr. Steven Edelman and his guest, director of the Center for Type 1 Diabetes Research at the La Jolla Institute for Allergy and Immunology, Dr. Matthias von Herrath, as they discuss histopathology, antigen-specific therapy, anti-CD3d antibodies and more.
Presenters
Facebook Comments